Материалов:
1 005 012

Репозиториев:
30

Авторов:
596 024

По вашему запросу найдено документов: 306980

Страница 1 из 30698

Immunotherapy against drug resistance as a therapy compliment increasing the duration of the effective use of art
E. . Starodubova, S. . Petkov, A. . Kilpelaeinen, O. . Krotova, A. . Latanova, O. . Latyshev, O. . Eliseeva, M Abakumov, A. . Tukhvatulin, I. . Gordeychuk, D. . Logunov, M. . Bobkova, M. . Mikhailov, M. . Saguliants
Immunotherapy against drug resistance as a therapy compliment increasing the duration
Adjuvantation of an influenza hemagglutinin antigen with tlr4 and nod2 agonists encapsulated in poly(D,l-lactide-co-glycolide) nanoparticles enhances immunogenicity and protection against lethal influenza virus infection in mice
Tukhvatulin A.
-recognition receptors (PRRs) belonging to different families. We prepared a model subunit vaccine formulation using
Camelid VHHs fused to human fc fragments provide long term protection against botulinum neurotoxin a in mice
Godakova Svetlana A.
The bacterium Clostridium botulinum is the causative agent of botulism—a severe intoxication caused
Stimulation of dectin-1 and dectin-2 during parenteral immunization, but not mincle, induces secretory IgA in intestinal mucosa
Dzharullaeva Alina S.
Induction of a robust and long-lived mucosal immune response during vaccination is critical
A heterologous virus-vectored vaccine for prevention of middle east respiratory syndrome induces long protective immune response against MERS-cov
Kovyrshina A. V.
system with a high mortality, caused by coronavirus MERS-CoV. At present moment, we still lack specific
Preclinical Studies of Immunogenity, Protectivity, and Safety of the Combined Vector Vaccine for Prevention of the Middle East Respiratory Syndrome
Dolzhikova I.V.
of MERS beyond its current confines, developing a vaccine is a pressing task, because vaccination would
Immunogenicity of different forms of middle east respiratory syndrome s glycoprotein
Ozharovskaia T.A.
in humans, with a fatality rate of ~35.5%. Currently, there are no registered vaccines or means
Neutralizing activity of sera from sputnik v-vaccinated people against variants of concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow endemic SARS-CoV-2 variants
Gushchin V.A., Dolzhikova I.V., Shchetinin A.M., Odintsova A.S., Siniavin A.E., Nikiforova M.A., Pochtovyi A.A., Shidlovskaya E.V., Kuznetsova N.A., Burgasova O.A., Kolobukhina L.V., Iliukhina A.A., Kovyrshina A.V., Botikov A.G., Kuzina A.V., Grousova D.M., Tukhvatulin A.I., Shcheblyakov D.V., Zubkova O.V., Karpova O.V., Voronina O.L., Ryzhova N.N., Aksenova E.I., Kunda M.S., Lioznov D.A., Danilenko D.M., Komissarov A.B., Tkachuck A.P., Logunov D.Y., Gintsburg A.L.
. There is a growing number of reports on mutations in receptor-binding domain (RBD) increasing
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., Botikov A.G., Izhaeva F.M., Popova O., Ozharovskaya T.A., Esmagambetov I.B., Favorskaya I.A., Zrelkin D.I., Voronina D.V., Shcherbinin D.N., Semikhin A.S., Simakova Y.V., Tokarskaya E.A., Egorova D.A., Shmarov M.M., Nikitenko N.A., Gushchin V.A., Smolyarchuk E.A., Zyryanov S.K., Borisevich S.V., Naroditsky B.S., Gintsburg A.L., Gam-COVID-Vac Vaccine Trial Group
Background: A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Logunov D.Y.
Background: A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V

Страница 1 из 30698

Фасеты

Новости проекта

Новости

Партнеры

КФУ
ТГУ
Elpub
СФУ
Webpublishers

Индексация

BASE
WorldCat
OpenAIRE
EDS
core